Bothell-based BioLife Solutions, Inc. has announced its customer Capricor Therapeutics announced positive six-month safety and adverse event data from its ongoing DYNAMIC (Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells) clinical trial evaluating CAP-1002 in patients with advanced heart failure. The data were highlighted in a poster presentation on Nov. 9 at the 2015 American Heart Association (AHA) Scientific Sessions in Orlando, Fla.

BioLife is a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers and Capricor Therapeutics is a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics.

BioLife’s CryoStor cryopreservation media is an integral component in the manufacturing process of CAP-1002 and is used to freeze and administer these therapeutic cells to heart failure patients.

“We are pleased that Capricor used our CryoStor cryopreservation media in its successful DYNAMIC trial,” said BioLife’s President and CEO Mike Rice. “We look forward to the results of the HOPE-Duchenne trial, which has recently opened for enrollment, and also the ALLSTAR Phase II trial. CryoStor is also used in these clinical trials. To date, CryoStor and our HypoThermosol and tissue storage and shipping media are now embedded in over 200 pre-clinical validations and clinical trials of new cell-based products and therapies.”

CAP-1002 is Capricor’s lead investigational allogeneic, cardiosphere-derived cell (CDC) therapy.

Multi-vessel intracoronary infusion of CAP-1002 in subjects with dilated cardiomyopathy was shown to be safe in this study with no major adverse cardiac events reported at one month or at six months post-infusion. Though this trial was intended as an early safety study, the six-month data demonstrated encouraging and congruent preliminary efficacy signals in multiple parameters, including subjective well being, exercise capacity, ejection fraction and ventricular volumes.